Form 4: Director Nicole Onetto Acquires 22,000 Stock Options in Bolt Biotherapeutics

Nicole Onetto, a director of Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024, exercisable at $0.7682 per share.

Summary

• On June 12, 2024, Nicole Onetto, a director of Bolt Biotherapeutics, acquired 22,000 stock options.
• The exercise price of these options is $0.7682 per share.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options will fully vest upon a change in control of Bolt Biotherapeutics.
• The expiration date for these options is June 11, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.

Future Outlook

The vesting of the options is contingent upon continued service and a potential change in control, indicating a long-term incentive for the director.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, common in the biotechnology industry to incentivize management and align their interests with shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing value creation.

Key Dates